Skip to main content
SpringerLink
Log in

Pathogenesis and Treatment of Aggressive Corticotroph Pituitary Tumors

  • Chapter
  • First Online:
The Hypothalamic-Pituitary-Adrenal Axis in Health and Disease

Abstract

Although the majority of corticotroph pituitary tumors are microadenomas and amenable to complete surgical resection, a subset exhibits a higher frequency of local invasiveness, tendency to recur, and potential to progress to carcinoma. Specifically, Crooke’s cell adenomas, silent corticotroph adenomas, and corticotroph tumors in the setting of Nelson’s syndrome are often more aggressive. These tumors may exhibit higher Ki-67 and/or p53 immunostaining though this is not uniform. Emerging molecular markers show promise but have not yet been validated in routine clinical use. Therapy is generally multimodal with surgical debulking to alleviate compressive symptoms, radiation therapy to prevent or delay tumor growth, and medical therapies to manage the many adverse metabolic consequences of hypercortisolism. However, many of these agents do not inhibit tumor growth and recently temozolomide, an alkylating chemotherapy agent, has been demonstrated to offer stabilization and in some instances partial and/or complete regression of these aggressive corticotroph tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Amar AP, Hinton DR, Kriegar MD, Weiss MH. Invasive pituitary adenomas: significance of proliferation parameters. Pituitary. 1999;2:117–22.

    Article  CAS  PubMed  Google Scholar 

  2. Heaney AP. Clinical review: pituitary carcinoma: difficult diagnosis and treatment. J Clin Endocrinol Metab. 2011;96:3649–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Meij BP, Lopes MB, Ellegala DB, Alden TD, Laws ER. The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery. J Neurosurg. 2002;92:195–208.

    Article  Google Scholar 

  4. Scheithauer BW, Kovacs K, Laws Jr ER, Randall RV. Pathology of invasive pituitary tumors with special reference to functional classification. J Neurosurg. 1986;65:733–44.

    Article  CAS  PubMed  Google Scholar 

  5. Thapar K, Kovacs K, Scheithauer BW, Stefaneanu L, Horvath E, Pernicone PJ, Murray D, Laws Jr ER. Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the M1B-1 antibody. Neurosurgery. 1996;38:99–106.

    Article  CAS  PubMed  Google Scholar 

  6. Trouillas J, Roy P, Sturm N, Dantony E, Cortet-Rudelli C, Viennet G, Bonneville JF, Assaker R, Auger C, Brue T, Cornelius A, Dufour H, Jouanneau E, Francois P, Galland F, Mougel F, Chapuis F, Villeneuve L, Maurage CA, Figarella-Branger D, Raverot G, the members of HYPOPRONOS. A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol. 2013;126:123–35.

    Article  PubMed  Google Scholar 

  7. Raverot G, Vasiljevic A, Jouanneau E, Trouillas J. A prognostic clinicopathologic classification of pituitary endocrine tumors. Endocrinol Metab Clin North Am. 2015;44:11–8.

    Article  PubMed  Google Scholar 

  8. Di leva A, Rotondo F, Syro L, Cusimano MD, Kovacs K. Aggressive pituitary adenomas—diagnosis and emerging treatments. Nat Rev Endocrinol. 2014;10:423–35.

    Article  CAS  Google Scholar 

  9. Crooke A. A change in the basophil cells of the pituitary gland common to conditions which exhibit the syndrome attributed to basophil adenoma. J Pathol Bacteriol. 1935;41:339–49.

    Article  Google Scholar 

  10. DeCicco FA, Dekker A, Yunis EJ. Fine structure of Crooke’s hyaline change in the human pituitary gland. Arch Pathol. 1972;94:65–70.

    CAS  PubMed  Google Scholar 

  11. Rotondo F, Cusimano M, Scheithauer BW, Coire C, Horvath E, Kovacs K. Atypical, invasive, recurring Crooke cell adenoma of the pituitary. Hormones. 2012;11:94–100.

    PubMed  Google Scholar 

  12. Di leva A, Davidson JM, Syro LV, Rotondo F, Montoya JF, Horvath E, Cusimano MD, Kovacs K. Crooke’ cell tumors of the pituitary. Neurosurgery. 2015;76:616–22.

    Article  Google Scholar 

  13. George DH, Scheithauer BW, Kovacs K, Horvath E, Young Jr WF, Llyod RV, Meyer FB. Crooke’s cell adenoma of the pituitary: an aggressive variant of corticotroph adenoma. Am J Surg Pathol. 2003;27:1330–6.

    Article  PubMed  Google Scholar 

  14. Mete O, Hayhurst C, Alahmadi H, Monsalves E, Gucer H, Gentili F, Ezzat S, Asa SL, Zadeh G. The role of mediators of cell invasiveness, motility, and migration in the pathogenesis of silent corticotroph adenomas. Endocr Pathol. 2013;24:191–8.

    Article  PubMed  Google Scholar 

  15. Kovacs K, Horvath E, Bayley TA, Hassaram ST, Ezrin C. Silent corticotroph cell adenoma with lysosomal accumulation and crinophagy: a distinct clinicopathologic entity. Am J Med. 1978;64:492–9.

    Article  CAS  PubMed  Google Scholar 

  16. Tateno T, Izumiyama H, Doi M, Yoshimoto T, Shichiri M, Inoshita N, Hirata Y. Differential gene expression in ACTH-secreting and non-functioning pituitary tumors. Eur J Endocrinol. 2007;6:717–24.

    Article  CAS  Google Scholar 

  17. Raverot G, Wierinckx A, Jouanneau E, Auger C, Borson-Chazot F, Lachuer J, Trouillas J. Clinical, hormonal and molecular characterization of pituitary ACTH adenomas without (silent corticotroph adenomas) and with Cushing’s disease. Eur J Endocrinol. 2010;1:35–43.

    Article  CAS  Google Scholar 

  18. Ohta S, Nishizawa S, Oki Y, Yokoyama T, Namba H. Significance of absent prohormone convertase 1/3 in inducing clinically silent corticotroph pituitary adenoma of subtype I-immunohistochemical study. Pituitary. 2002;4:221–3.

    Article  Google Scholar 

  19. Cooper O, Melmed S. Subclinical hyperfunctioning pituitary adenomas: the silent tumors. Best Pract Res Clin Endocrinol Metab. 2012;26:447–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Karavitaki N, Ansorge O, Wass JA. Silent corticotroph adenomas. Arq Bras Endocrinol Metab. 2007;51:1314–8.

    Article  Google Scholar 

  21. Baldeweg SE, Pollock JR, Powell M, Ahlquist J. A spectrum of behavior in silent corticotroph pituitary adenomas. Br J Neurosurg. 2005;19:38–42.

    Article  CAS  PubMed  Google Scholar 

  22. Pawlikowski M, Kunert-Radek J, Radek M. “Silent” corticotropinoma. Neur Endocrinol Lett. 2008;29:347–50.

    Google Scholar 

  23. Scheithauer BW, Jaap AJ, Horvath E, Kovacs K, Lloyd RV, Meyer FB, Law Jr ER, Young Jr WF. Clinically silent corticotroph tumors of the pituitary gland. Neurosurg. 2000;47:723–9.

    CAS  Google Scholar 

  24. Alahmadi H, Lee D, Wilson JR, Hayhurst C, Mete O, Gentili F, Asa S, Zadeh G. Clinical features of silent corticotroph adenomas. Acta Neurochir. 2012;154:1493–8.

    Article  PubMed  Google Scholar 

  25. Bradley KJ, Wass JAH, Turner HE. Non-functioning pituitary adenomas with positive immunoreactivity for ACTH behave more aggressively than ACTH immunonegative tumors but do not recur more frequently. Clin Endocrinol (Oxf). 2003;58:59–64.

    Article  CAS  Google Scholar 

  26. Nelson DH, Meakin JW, Dealy JW. ACTH-producing tumors of the pituitary gland. N Engl J Med. 1958;259:161–4.

    Article  CAS  PubMed  Google Scholar 

  27. Jordan RM, Cook DM, Kendall JW, Kerber CW. Nelson’s syndrome and spontaneous pituitary tumor infarction. Arch Intern Med. 1979;139:340–2.

    Article  CAS  PubMed  Google Scholar 

  28. Jenkins PJ, Trainer PJ, Plowman PN, Shand WS, Grossman AB, Wass JA, Besser GM. The long-term outcome after adrenalectomy and prophylactic radiotherapy in adrenocorticotrophin-dependent Cushing’s syndrome. J Clin Endocrinol Metab. 1995;80:165–71.

    CAS  PubMed  Google Scholar 

  29. Assié G, Bahurel H, Coste J, Silvera S, Kujas M, Dugué MA, Karray F, Dousset B, Bertherat J, Legmann P, Bertagna X. Corticotroph tumor progression after adrenalectomy in Cushing’s disease: a reappraisal of Nelson’s syndrome. J Clin Endocrinol Metab. 2007;92:172–9.

    Article  PubMed  CAS  Google Scholar 

  30. Salehi F, Agur A, Scheithauer BW, Kovacs K, Lloyd RV, Cusimano M, Cusimano M. Ki-67 in pituitary neoplasms: a review-Part I. Neurosurgery. 2009;65:429–37.

    Article  PubMed  Google Scholar 

  31. Heaney A. Management of aggressive pituitary adenomas and pituitary carcinomas. J Neurooncol. 2014;117:459–68.

    Article  CAS  PubMed  Google Scholar 

  32. Mastronardi L, Guiducci A, Spera C, Puzzilli F, Liberati F, Maira G. Ki-67 labelling index and invasiveness among anterior pituitary adenomas: analysis of 103 cases using the MIB-1 monoclonal antibody. J Clin Pathol. 1999;52:107–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Scheithauer BW, Gaffey TA, Lloyd RV, Sebo TJ, Kovacs KT, Horvath E, Yapicier O, Young Jr WF, Meyer FB, Kuroki T, Riehle DL, Laws Jr ER. Pathobiology of pituitary adenomas and carcinomas. Neurosurgery. 2006;59:341–53.

    Article  PubMed  Google Scholar 

  34. Horvath E, Kovacs K, Killinger DW, Smyth HS, Platts ME, Singer W. Silent corticotropic adenomas of the human pituitary gland: a histologic, immunocytologic, and ultrastructural study. Am J Pathol. 1980;98:617–38.

    CAS  PubMed  PubMed Central  Google Scholar 

  35. Kontogeorgos G. Classification and pathology of pituitary tumors. Endocrine. 2005;28:27–35.

    Article  CAS  PubMed  Google Scholar 

  36. Kaltsas GA, Grossman AB. Malignant pituitary tumors. Pituitary. 1998;69–81.

    Google Scholar 

  37. Gadelha MR, Trivellin G, Hernandez Ramirez LC, Korbonits M. Genetics of pituitary adenomas. Front Horm Res. 2013;41:111–40.

    Article  CAS  PubMed  Google Scholar 

  38. Westermarck M, Seth A, Kahari VM. Differential regulation of interstitial collagenase (MMP-1) gene expression by ETS transcription factors. Oncogene. 1997;14:2651–60.

    Article  CAS  PubMed  Google Scholar 

  39. Rutter JL, Mitchell TI, Buttice G, Meyers J, Gusella JF, Ozelius LJ, Brinckerhoff CE. A single nucleotide polymorphism in the matrix metalloproteinase-1 promotor creates an Ets binding site and augments transcription. Cancer Res. 1998;58:5321–5.

    CAS  PubMed  Google Scholar 

  40. Atlas M, Bayrak OF, Ayan E, Bolukbasi F, Silav G, Coskun KK, Culha M, Sahin F, Sevli S, Elmaci I. The effect of polymorphism sin the promotor region of the MMP-1 gene on the occurrence and invasiveness of hypophyseal adenoma. Acta Neurochir. 2010;152:1611–7.

    Article  Google Scholar 

  41. Chakraborti S, Mandal M, Das S, Mandal A, Chakraborti T. Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem. 2003;253:269–85.

    Article  CAS  PubMed  Google Scholar 

  42. Kawamoto H, Kawamoto K, Mizoue T, Uozumi T, Arita K, Kurisu K. Matrix metalloproteinase-9 secretion by human pituitary adenomas detected by cell immunoblot analysis. Acta Neurochir. 1996;138:1442–8.

    Article  CAS  PubMed  Google Scholar 

  43. Liu W, Matsumoto Y, Okada M, Miyake K, Kunishio K, Kawai N, Tamiya T, Nagao S. Matrix metalloproteinase 2 and 9 expression correlated with cavernous sinus invasion of pituitary adenomas. J Med Invest. 2005;52:151–8.

    Article  PubMed  Google Scholar 

  44. Hussaini IM, Trotter C, Zhao Y, Abdel-Fattah R, Amos S, Xiao A, Agi CU, Redpath GT, Fang Z, Leung GK. Matrix metalloproteinase-9 is differentially expressed in nonfunctioning invasive and noninvasive pituitary adenomas and increases invasion in human pituitary adenoma cell line. Am J Pathol. 2007;170:356–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Sugiyama N, Varjosalo M, Meller P, Lohi J, Chan KM, Zhou Z, Alitalo K, Taipale J, Keski-Oja J, Lehti K. FGF receptor-4 (FGFR4) polymorphism acts as an activity switch of a membrane type 1 matrix metalloproteinase-FGFR4 complex. Proc Natl Acad Sci U S A. 2010;107:15786–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Sanchez-Ortiga R, Sanchez-Tejada L, Moreno-Perez O, Riesgo P, Niveiro M, Pico Alfonso AM. Over-expression of vascular endothelial growth factor in pituitary adenomas is associated with extrasellar growth and recurrence. Pituitary. 2013;16:370–7.

    Article  CAS  PubMed  Google Scholar 

  47. Jia W, Sander AJ, Jia G, Ni M, Liu X, Lu R, Jiang WG. Vascular endothelial growth inhibitor (VEGI) is an independent indicator for invasion in human pituitary adenomas. Anticancer Res. 2013;33:3815–22.

    PubMed  Google Scholar 

  48. Cornelius A, Cortet-Rudelli C, Assaker R, Kerdraon O, Gevaert MH, Prevot V, Lassalle P, Trouillas J, Delehedde M, Maurage CA. Endothelial expression of endocan is strongly associated with tumor progression in pituitary adenoma. Brain Pathol. 2012;22:757–64.

    Article  CAS  PubMed  Google Scholar 

  49. Matano F, Yoshida D, Ishii Y, Tahara S, Teramoto A, Morita A. Endocan, a new invasion and angiogenesis marker of pituitary adenomas. J Neurooncol. 2014;117:485–91.

    Article  CAS  PubMed  Google Scholar 

  50. Trouillas J, Labat-Moleur F, Sturm N, Kujas M, Heymann MF, Flgarella-Branger D, Paley M, Mazucca M, Decullier E, Verges B, Chabre O, Calender A, Grouped’etudes des Tumeurs Endocrines. Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients. Am J Surg Pathol. 2008;32:534–43.

    Article  PubMed  Google Scholar 

  51. Toledo SP, Lourenco DM, Toledo RA. A differential diagnosis of inherited endocrine tumors and their tumor counterparts. Clinics (San Paulo). 2013;68:1039–56.

    Article  Google Scholar 

  52. Tahir A, Chahal HS, Korbonits M. Molecular genetics of the AIP gene in familial pituitary tumorigenesis. Prog Brain Res. 2010;182:229–53.

    Article  CAS  PubMed  Google Scholar 

  53. Newey PJ, Thakker RV. Role of multiple endocrine neoplasia type I mutational analysis in clinical practice. Endocr Pract. 2011;17 Suppl 3:8–17.

    Article  PubMed  Google Scholar 

  54. Bates AS, Farrell WE, Bicknell JE, McNicol AM, Talbot JA, Broome JC, Perrett CW, Thakker RV, Clayton RN. Genetic instability in pituitary adenomas reflects aggressive biological activity and has potential value as a prognostic marker. J Clin Endocrinol Metab. 1997;82:818–24.

    CAS  PubMed  Google Scholar 

  55. Cai WY, Alexander JM, Hedley-Whyte ET, Scheithauer BW, Jameson JL, Zervas NT, Klibanski A. Ras mutations in human prolactinomas and pituitary carcinomas. J Clin Endocrinol Metab. 1994;78:89–93.

    CAS  PubMed  Google Scholar 

  56. Wierinckx A, Auger C, Devauchelle P, Raynaud A, Chevallier P, Jan M, Perrin G, Fevre-Montagne M, Rey C, Figarella-Baranger D, Raverot G, Belin MF, Lachuer J, Trouillas J. A diagnostic maker set for invasion, proliferation and aggressiveness of prolactin pituitary tumors. Endocr Relat Cancer. 2007;14:887–900.

    Article  CAS  PubMed  Google Scholar 

  57. Zhang X, Horwitz GA, Heaney AP, Nakashima M, Prezant TP, Bronstein MD, Melmed S. Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. J Clin Endocrinol Metab. 1999;84:761–7.

    Article  CAS  PubMed  Google Scholar 

  58. Reincke M, Sbiera S, Hayakawa A, Theodoropoulou M, Osswald A, Beuschlein F, Meitinger T, Mizuno-Yamasaki E, Kawaguchi K, Saeki Y, Tanaka K, Wieland T, Graf E, Saeger W, Ronchi C, Allolio B, Buchfelder M, Strom TM, Fassnacht M, Koada M. Mutations in the deubiquitinase gene USP8 cause Cushing’s disease. Nat Genet. 2015;47:31–8.

    Article  CAS  PubMed  Google Scholar 

  59. Riebold M, Kozany C, Freiburger L, Sattler M, Buchfelder M, Hausch F, Stalla GK, Paez-Pereda M. A C-terminal HSP90 inhibitor restores glucocorticoid sensitivity and relieves a mouse allograft model of Cushing disease. Nat Med. 2015;21:276–8.

    CAS  PubMed  Google Scholar 

  60. Nieman L, Biller BM, Findling JW, Newell-Price J, Savage MO, Stewart PM, Montori VM. The diagnosis of Cushing’s syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2008;93:1526–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Tritos NA, Biller BM. Cushing’s disease. Handb Clin Neurol. 2014;124:221–34.

    Article  PubMed  Google Scholar 

  62. Ayala A, Manzano A. Detection of recurrent Cushing’s disease: proposal for standardized patient monitoring following transsphenoidal surgery. J Neurooncol. 2014;119:235–42.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Roelfsema F, Biermasz NR, Pereira AM. Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis. Pituitary. 2012;15:71–83.

    Article  PubMed  Google Scholar 

  64. Zada G, Woodmansee WW, Ramkissoon S, Amadio J, Nose V, Laws Jr ER. Atypical pituitary adenomas: incidence, clinical characteristics, and implications. J Neurosurg. 2011;114:336–44.

    Article  PubMed  Google Scholar 

  65. Tritos NA, Biller BM. Update on radiation therapy in patients with Cushing’s disease. Pituitary. 2015;18:263–8.

    Article  CAS  PubMed  Google Scholar 

  66. Petit JH, Biller BM, Yock TI, Swearingen B, Coen JJ, Chapman P, Ancukiewicz M, Bussiere M, Klibanski A, Loeffler JS. Proton stereotactic radiotherapy for persistent adrenocorticotropin-producing adenoma. J Clin Endocrinol Metab. 2008;93:393–9.

    Article  CAS  PubMed  Google Scholar 

  67. Wattson DA, Tanguturi K, Spiegel DY, Neimieko A, Biller BM, Nachtigall LB, Bussiere MR, Swearingen B, Chapman PH, Loeffler JS, Shih HA. Outcomes of proton therapy for patients with functional pituitary adenomas. Int J Radiat Oncol Biol Phys. 2014;90:532–9.

    Article  PubMed  Google Scholar 

  68. Sheehan JP, Xu Z, Salvetti DJ, Schmitt PJ, Vance ML. Results of gamma knife surgery for Cushing’s disease. J Neurosurg. 2013;119:1486–92.

    Article  PubMed  Google Scholar 

  69. Molitch ME. Current approaches to the pharmacological management of Cushing’s disease. Mol Cell Endocrinol. 2015;408:185–9.

    Article  CAS  PubMed  Google Scholar 

  70. Praw SS, Heaney AP. Medical treatment of Cushing’s disease: overview and recent findings. Int J Gen Med. 2009;2:209–17.

    CAS  PubMed  PubMed Central  Google Scholar 

  71. Fleseriu M. Medical treatment of Cushing disease: new targets, new hope. Endocrinol Metab Clin North Am. 2015;44:51–70.

    Article  PubMed  Google Scholar 

  72. Fleseriu M, Biller BM, Findling JW, Molitch ME, Schteingart DE, Gross C, SEISMIC study investigators. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing’s syndrome. J Clin Endocrinol Metab. 2012;97:2039–49.

    Article  CAS  PubMed  Google Scholar 

  73. Pivonello R, Ferone D, de Herder WW, Kros JM, De Caro ML, Arvigo M, Annunziato L, Lombardi G, Colao A, Hofland LJ, Lamberts SW. Dopamine receptor expression and function in corticotroph pituitary tumors. J Clin Endocrinol Metab. 2004;89:2452–62.

    Article  CAS  PubMed  Google Scholar 

  74. Pivonello R, Faggiano A, DiSalle F, Filippella M, Lombardi G, Colao A. Complete remission of Nelson’s syndrome after 1 year treatment with cabergoline. J Endocrinol Invest. 1999;22:860–5.

    Article  CAS  PubMed  Google Scholar 

  75. Tritos NA, Schaefer PW, Stein TD. Case records of the Massachusetts General Hospital Case 40-2011. A 52-year-old man with weakness, infections, and enlarged adrenal glands. N Engl J Med. 2011;365:2520–30.

    Article  CAS  PubMed  Google Scholar 

  76. Tyrrell JB, Lorenzi M, Gerich JE, Forsham PH. Inhibition by somatostatin of ACTH secretion in Nelson’s syndrome. J Clin Endocrinol Metab. 1975;6:1125–7.

    Article  Google Scholar 

  77. Strowski MZ, Dashkevicz MP, Parmar RM, Wilkinson H, Kohler M, Schaeffer JM, Blake AD. Somatostatin receptor subtypes 2 and 5 inhibit corticotropin-releasing hormone-stimulated adrenocorticotropin secretion from AtT-20 cells. Neuroendocrinology. 2002;75:339–46.

    Article  CAS  PubMed  Google Scholar 

  78. Lamberts SW, Uitterlinden P, Klijn JM. The effect of the long-acting somatostatin analogue SMS 201-995 on ACTH secretion in Nelson’s syndrome and Cushing’s disease. Acta Endocrinol (Copenh). 1989;120:760–6.

    CAS  Google Scholar 

  79. Bruns C, Lewis I, Briner U, Meno-tetang G, Weckbecker G. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol. 2002;5:707–16.

    Article  Google Scholar 

  80. Colao A, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Schoenherr U, Mills D, Salgodo LR, Biller BM. Pasireotide B2305 Study Group. A 12-month phase 3 study of pasireotide in Cushing’s disease. N Engl J Med. 2012;366:914–24.

    Article  CAS  PubMed  Google Scholar 

  81. Castinetti F, Morange I, Jaquet P, Conte-Devolx B, Brue T. Ketoconazole revisited: a preoperative or postoperative treatment in Cushing’s disease. Eur J Endocrinol. 2008;158:91–9.

    Article  CAS  PubMed  Google Scholar 

  82. Castinetti F, Guignat L, Giraud P, Muller M, Kamenicky P, Drui D, Caron P, Luca F, Donadille B, Vantyghem MC, Bihan H, Delemer B, Raverot G, Motte E, Philippon M, Morange I, Conte-Devolx B, Quinquis L, Marinie M, Vezzosi D, Le Bras M, Baudry C, Christin-Maitre S, Goichot B, Chanson P, Young J, Chabre O, Tabarin A, Bertherat J, Brue T. Ketoconazole in Cushing’s disease: is it worth a try? J Clin Endocrinol Metab. 2014;99:1623–30.

    Article  CAS  PubMed  Google Scholar 

  83. Verhelst JA, Trainer PJ, Howlett TA, Perry L, Rees LH, Grossman AB, Wass JA, Besser GM. Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing’s syndrome. Clin Endocrinol (Oxf). 1991;35:169–78.

    Article  CAS  Google Scholar 

  84. Daniel E, Aylwin S, Mustafa O, Ball S, Munir A, Boelaert K, Chortis V, Cuthbertson DJ, Daousi C, Rajeev SP, Davis J, Cheer K, Drake W, Gunganah K, Grossman A, Gurnell M, Powlson AS, Karavitaki N, Huguet I, Kearney T, Mohit K, Meeran K, Hill N, Rees A, Lansdown AJ, Trainer PJ, Minder AE, Newell-Price J. Effectiveness of metyrapone in treating Cushing’s syndrome: a retrospective multicenter study in 195 patients. J Clin Endocrinol Metab. 2015;100:4146–54.

    Article  CAS  PubMed  Google Scholar 

  85. Lim S, Shahinian H, Maya MM, Yong W, Heaney AP. Temozolomide: a novel treatment for pituitary carcinoma. Lancet Oncol. 2006;7:518–20.

    Article  PubMed  Google Scholar 

  86. Hagen C, Schroeder HD, Hansen S, Hagen C, Andersen M. Temozolomide treatment in a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy. Eur J Endocrinol. 2009;161:631–7.

    Article  CAS  PubMed  Google Scholar 

  87. Ortiz LD, Syro LV, Scheithauer BW, Rotonda F, Uribe H, Fadul CE, Horvath E, Kovacs K. Temozolomide in aggressive pituitary adenomas and carcinomas. Clinics. 2012;67:119–23.

    Article  PubMed  PubMed Central  Google Scholar 

  88. Zhang J, Stevens MG, Bradshaw TD. Temozolomide: mechanisms of action, repair and resistance. Curr Mol Pharmacol. 2012;5:102–14.

    Article  CAS  PubMed  Google Scholar 

  89. Friedman HS, McLendon RE, Kerby T, Dugan M, Bigner SH, Henry AJ, Ashley DM, Krischer J, Lovell S, Rasheed K, Marchev F, Seman AJ, Cokgor I, Rich J, Stewart E, Colvin OM, Provenzale JM, Bigner DD, Haglund MM, Friedman AH, Modrich PL. DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol. 1998;16:3851–7.

    CAS  PubMed  Google Scholar 

  90. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997–1003.

    Article  CAS  PubMed  Google Scholar 

  91. Bengtsson D, Schroder HD, Andersen M, Maiter D, Berinder K, FeldtRasmuseen U, Rasmussen AK, Johannsoon G, Hoybye C, van der Lely AJ, Pegtersson M, Ragnarsson O, Burman P. Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide. J Clin Endocrinol Metab. 2015;100:1689–98.

    Article  CAS  PubMed  Google Scholar 

  92. Raverot G, Sturm N, de Fraipont F, Muller M, Salenave S, Caron P, Chabre O, Chanson P, Cortet-Rudelli C, Assaker R, Dufour H, Gaillard S, Francois P, Jouanneau E, Passagia JG, Berneir M, Cornelius A, Figarella-Branger D, Trouillas J, Borson-Chazot F, Brue T. Temozolomide treatment of aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J Clin Endocrinol Metab. 2010;95:4592–9.

    Article  CAS  PubMed  Google Scholar 

  93. Bush ZM, Longtine JA, Cunningham T, Schiff D, Jane Jr JA, Vance ML, Thorner MO, Laws Jr ER, Lopes MB. Temozolomide treatment for aggressive pituitary tumors: correlation of clinic outcome with O6-methylguanine methyltransferase (MGMT) promotor methylation and expression. J Clin Endocrinol Metab. 2010;95:E280–90.

    Article  PubMed  Google Scholar 

  94. Hirohata T, Asano K, Takano S, Amano K, Isozaki O, Iwai Y, Sakata K, Fukuhara N, Nishioka H, Yamada S, Fujio S, Arita K, Takano K, Tominaga A, Hizuka N, Ikeda H, Osamura RY, Tahara S, Ishii Y, Kawamata T, Shimatsu A, Teramoto A, Matsuno A. DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: the national cooperative study by the Japan Society for Hypothalamic and Pituitary Tumors. J Clin Endocrinol Metab. 2013;98:1130–6.

    Article  CAS  PubMed  Google Scholar 

  95. Mohammed S, Kovacs K, Mason W, Smyth H, Cusimano MD. Use of temozolomide in aggressive pituitary tumors: case report. Neurosurgery. 2009;64:E773–4.

    Article  PubMed  Google Scholar 

  96. Moyes VJ, Alusi G, Sabin HI, Evanson J, Berney DM, Kovacs K, Monson JP, Plowman PN, Drake WM. Treatment of Nelson’s syndrome with temozolomide. Eur J Endocrinol. 2009;160:115–9.

    Article  CAS  PubMed  Google Scholar 

  97. Kurowska M, Nowakowski A, Zielinski G, Malicka J, Tarach JS, Maksymowicz M, Denew P. Temozolomide-induced shrinkage of invasive pituitary adenoma in patient with Nelson’s syndrome: A case report and review of the literature. Case Rep Endocrinol. 2015;2015:623092. doi:10.1155/2015/623092.

    PubMed  PubMed Central  Google Scholar 

  98. Dillard TH, Gultekin SH, Delashaw Jr JB, Yedinak CG, Neuwelt EA, Fleseriu M. Temozolomide for corticotroph pituitary adenomas refractory to standard therapy. Pituitary. 2011;14:80–91.

    Article  CAS  PubMed  Google Scholar 

  99. Annamalai AK, Dean AF, Kandasamy N, Kovacs K, Burton H, Halsall DJ, Shaw AS, Antoun NM, Cheow HK, Kirollos RW, Pickard JD, Simpson HL, Jefferies SJ, Burnet NG, Gurnell M. Temozolomide responsiveness in aggressive corticotroph tumors: a case report and review of the literature. Pituitary. 2012;15:276–87.

    Article  CAS  PubMed  Google Scholar 

  100. Moshkin O, Syro LV, Scheithauer BW, Ortiz LD, Fadul CE, Uribe H, Gonzalez R, Cusimano M, Horvath E, Rotondo F, Kovacs K. Aggressive silent corticotroph adenoma progressing to pituitary carcinoma: the role of temozolomide therapy. J Neurooncol. 2015;122:189–96.

    Article  CAS  Google Scholar 

  101. Curto L, Torre ML, Ferrau F, Pitini V, Altavilla G, Granata F, Longo M, Hofland LJ, Trimarchi F, Cannavo S. Temozolomide-induced shrinkage of a pituitary carcinoma causing Cushing’s disease – report of a case and literature review. Scientific World Journal. 2010;10:2132–8.

    Article  CAS  PubMed  Google Scholar 

  102. Zacharia BE, Gulati AP, Bruce JN, Carminucci AS, Wardlaw SL, Siegelin M, Remotti H, Lignelli A, Fine RL. High response rates and prolonged survival in patients with corticotroph pituitary tumors and refractory Cushing disease from capecitabine and temozolomide (CAPTEM): a case series. Neurosurgery. 2014;74:E447–55.

    Article  PubMed  Google Scholar 

  103. Fine RL, Gulati AP, Krantz BA, Moss RA, Schreibman S, Tsushima DA, Mowatt KB, Dinnen RD, Mao Y, Stevens PD, Schrope B, Allendorf J, Lee JA, Sherman WH, Chabot JA. Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience. Cancer Chemother Pharmacol. 2013;71:663–70.

    Article  CAS  PubMed  Google Scholar 

  104. Raverot G, Jouanneau E, Trouillas J. Clinicopathological classification and molecular markers of pituitary tumours for personalized therapeutic strategies. Eur J Endocrinol. 2014;170:R121–32.

    Article  CAS  PubMed  Google Scholar 

  105. Monsalves E, Juraschka K, Tateno T, Agnihotri S, Asa SL, Ezzat S, Zadeh G. The PI3K/AKT/mTOR pathway in the pathophysiology and treatment of pituitary adenomas. Endocr Relat Cancer. 2014;21:R331–44.

    Article  CAS  PubMed  Google Scholar 

  106. Ortiz LD, Syro LV, Scheithauer BW, Ersen A, Uribe H, Fadul CE, Rotondo F, Horvath E, Kovacs K. Anti-VEGF therapy in pituitary carcinoma. Pituitary. 2012;15:445–9.

    Article  PubMed  Google Scholar 

  107. Jouanneau E, Wierinckx A, Ducray F, Favrel V, Borson-Cchazot F, Honnorat J, Trouillas J, Raverot G. New targeted therapies in pituitary carcinoma resistant to temozolomide. Pituitary. 2012;15:37–43.

    Article  CAS  PubMed  Google Scholar 

  108. Corsello SM, Barnabei A, Marchetti P, De Vecchis L, Salvatori R, Torino F. Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab. 2013;98:1361–75.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Indiana University School of Medicine/IU Health Arnett Clinic, Indianapolis, IN, 46202, USA

    Yang Shen M.D.

  2. UCLA School of Medicine, 200 UCLA Medical Plaza, suite 530, Los Angeles, CA, 90095, USA

    Anthony P. Heaney M.D., Ph.D.

Authors
  1. Yang Shen M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anthony P. Heaney M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anthony P. Heaney M.D., Ph.D. .

Editor information

Editors and Affiliations

  1. Division of Endocrinology, Multidisciplinary Pituitary and Skull Base Tumor Center, Memorial Sloan Kettering Cancer Center, New York, New York, USA

    Eliza B. Geer

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Shen, Y., Heaney, A.P. (2017). Pathogenesis and Treatment of Aggressive Corticotroph Pituitary Tumors. In: Geer, E. (eds) The Hypothalamic-Pituitary-Adrenal Axis in Health and Disease. Springer, Cham. https://doi.org/10.1007/978-3-319-45950-9_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-45950-9_5

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-45948-6

  • Online ISBN: 978-3-319-45950-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation